Skip to main content
Top
Published in: Surgery Today 5/2021

01-05-2021 | Metastasis | Original Article

Relationship between the tumor location and clinicopathological features in left-sided pancreatic ductal adenocarcinoma

Authors: Teijiro Hirashita, Yukio Iwashita, Atsuro Fujinaga, Hiroaki Nakanuma, Takashi Masuda, Yuichi Endo, Masayuki Ohta, Masafumi Inomata

Published in: Surgery Today | Issue 5/2021

Login to get access

Abstract

Purpose

Although the same distal pancreatectomy (DP) is performed regardless of the location of left-sided pancreatic ductal adenocarcinoma (PDAC), the clinicopathological features may differ depending on the tumor location. The present study investigated the relationship between the tumor location and clinicopathological features in patients with left-sided PDAC.

Methods

The records of 59 patients who underwent DP for PDAC were enrolled. The relationship between the tumor location and clinicopathological features was investigated. The tumor location was classified into three groups according to the 7th AJCC/UICC TNM classification: body (Pb), body and tail (Pbt), and tail (Pt).

Results

Tumors were located at the Pb in 26 patients, Pbt in 15, and Pt in 18. There was no metastasis to the lymph nodes around the common hepatic artery in Pt. The rate of peritoneal dissemination in the Pt was higher than that in the Pb (P = 0.034) or Pbt (P = 0.002). There were no significant differences in the overall survival among the three groups.

Conclusion

There was no metastasis to the lymph nodes around the common hepatic artery, and peritoneal dissemination was the most common site of recurrence in Pt tumors.
Literature
1.
go back to reference Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6:699–708.CrossRef Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6:699–708.CrossRef
2.
go back to reference Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133:521–7.CrossRef Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133:521–7.CrossRef
3.
go back to reference Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.CrossRef Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.CrossRef
4.
go back to reference Shimada K, Sakamoto Y, Sano T, Kosuge T. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery. 2006;139:288–95.CrossRef Shimada K, Sakamoto Y, Sano T, Kosuge T. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery. 2006;139:288–95.CrossRef
5.
go back to reference Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156:591–600.CrossRef Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156:591–600.CrossRef
6.
go back to reference Society JP. Classification of pancreatic carcinoma, 4th. English ed. Tokyo: Kanehara & Co., Ltd.; 2017. Society JP. Classification of pancreatic carcinoma, 4th. English ed. Tokyo: Kanehara & Co., Ltd.; 2017.
7.
go back to reference Sobin LHGM, Wittekind C. TNM classification of malignant tumors. 7th ed. New York: Wiley; 2010. Sobin LHGM, Wittekind C. TNM classification of malignant tumors. 7th ed. New York: Wiley; 2010.
8.
go back to reference Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.CrossRef Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.CrossRef
9.
go back to reference Chun YS. Role of radical antegrade modular pancreatosplenectomy (ramps) and pancreatic cancer. Ann Surg Oncol. 2018;25:46–50.CrossRef Chun YS. Role of radical antegrade modular pancreatosplenectomy (ramps) and pancreatic cancer. Ann Surg Oncol. 2018;25:46–50.CrossRef
11.
go back to reference Abe T, Ohuchida K, Miyasaka Y, Ohtsuka T, Oda Y, Nakamura M. Comparison of surgical outcomes between radical antegrade modular pancreatosplenectomy (RAMPS) and standard retrograde pancreatosplenectomy (SPRS) for s. World J Surg. 2016;40:2267–75.CrossRef Abe T, Ohuchida K, Miyasaka Y, Ohtsuka T, Oda Y, Nakamura M. Comparison of surgical outcomes between radical antegrade modular pancreatosplenectomy (RAMPS) and standard retrograde pancreatosplenectomy (SPRS) for s. World J Surg. 2016;40:2267–75.CrossRef
12.
go back to reference Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007;204:244–9.CrossRef Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007;204:244–9.CrossRef
13.
go back to reference Hank T, Hinz U, Tarantino I, Kaiser J, Niesen W, Bergmann F, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg. 2018;105:1171–81.CrossRef Hank T, Hinz U, Tarantino I, Kaiser J, Niesen W, Bergmann F, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg. 2018;105:1171–81.CrossRef
14.
go back to reference Murakawa M, Aoyama T, Asari M, Katayama Y, Yamaoku K, Kanazawa A, et al. The short- and long-term outcomes of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. BMC Surg. 2015;15:120.CrossRef Murakawa M, Aoyama T, Asari M, Katayama Y, Yamaoku K, Kanazawa A, et al. The short- and long-term outcomes of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. BMC Surg. 2015;15:120.CrossRef
15.
go back to reference Malleo G, Maggino L, Ferrone CR, Marchegiani G, Mino-Kenudson M, Capelli P, et al. Number of examined lymph nodes and nodal status assessment in distal pancreatectomy for body/tail ductal adenocarcinoma. Ann Surg. 2019;270:1138–46.CrossRef Malleo G, Maggino L, Ferrone CR, Marchegiani G, Mino-Kenudson M, Capelli P, et al. Number of examined lymph nodes and nodal status assessment in distal pancreatectomy for body/tail ductal adenocarcinoma. Ann Surg. 2019;270:1138–46.CrossRef
16.
go back to reference Fujita T, Nakagohri T, Gotohda N, Takahashi S, Konishi M, Kojima M, et al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas. 2010;39:e48–54.CrossRef Fujita T, Nakagohri T, Gotohda N, Takahashi S, Konishi M, Kojima M, et al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas. 2010;39:e48–54.CrossRef
17.
go back to reference Marmor S, Burke EE, Portschy PR, Virnig BA, Jensen EH, Tuttle TM. Lymph node evaluation for treatment of adenocarcinoma of the pancreas. Surg Oncol. 2015;24:284–91.CrossRef Marmor S, Burke EE, Portschy PR, Virnig BA, Jensen EH, Tuttle TM. Lymph node evaluation for treatment of adenocarcinoma of the pancreas. Surg Oncol. 2015;24:284–91.CrossRef
18.
go back to reference Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140:584–9.CrossRef Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140:584–9.CrossRef
19.
go back to reference Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin TT, et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas. 2011;40:951–5.CrossRef Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin TT, et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas. 2011;40:951–5.CrossRef
21.
go back to reference Malinka T, Klein F, Andreou A, Pratschke J, Bahra M. Distal pancreatectomy combined with multivisceral resection is associated with postoperative complication rates and survival comparable to those after standard procedures. J Gastrointest Surg. 2018;22:1549–56.CrossRef Malinka T, Klein F, Andreou A, Pratschke J, Bahra M. Distal pancreatectomy combined with multivisceral resection is associated with postoperative complication rates and survival comparable to those after standard procedures. J Gastrointest Surg. 2018;22:1549–56.CrossRef
22.
go back to reference Paye F, Micelli Lupinacci R, Bachellier P, Boher JM, Delpero JR. Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment. Br J Surg. 2015;102:229–36.CrossRef Paye F, Micelli Lupinacci R, Bachellier P, Boher JM, Delpero JR. Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment. Br J Surg. 2015;102:229–36.CrossRef
23.
go back to reference Hamidian Jahromi A, Jafarimehr E, Dabbous HM, Chu Q, D'Agostino H, Shi R, et al. Curative resection of pancreatic adenocarcinoma with major venous resection/repair is safe procedure but will not improve survival. JOP. 2014;15:433–41.PubMed Hamidian Jahromi A, Jafarimehr E, Dabbous HM, Chu Q, D'Agostino H, Shi R, et al. Curative resection of pancreatic adenocarcinoma with major venous resection/repair is safe procedure but will not improve survival. JOP. 2014;15:433–41.PubMed
24.
go back to reference Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 2016;103:179–91.CrossRef Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 2016;103:179–91.CrossRef
25.
go back to reference Hirono S, Kawai M, Tani M, Okada K, Miyazawa M, Shimizu A, et al. Indication for the use of an interposed graft during portal vein and/or superior mesenteric vein reconstruction in pancreatic resection based on perioperative outcomes. Langenbecks Arch Surg. 2014;399:461–71.CrossRef Hirono S, Kawai M, Tani M, Okada K, Miyazawa M, Shimizu A, et al. Indication for the use of an interposed graft during portal vein and/or superior mesenteric vein reconstruction in pancreatic resection based on perioperative outcomes. Langenbecks Arch Surg. 2014;399:461–71.CrossRef
Metadata
Title
Relationship between the tumor location and clinicopathological features in left-sided pancreatic ductal adenocarcinoma
Authors
Teijiro Hirashita
Yukio Iwashita
Atsuro Fujinaga
Hiroaki Nakanuma
Takashi Masuda
Yuichi Endo
Masayuki Ohta
Masafumi Inomata
Publication date
01-05-2021
Publisher
Springer Singapore
Published in
Surgery Today / Issue 5/2021
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02151-y

Other articles of this Issue 5/2021

Surgery Today 5/2021 Go to the issue